Rigel Pharmaceuticals, Inc. (RIGL)
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026
Rigel Pharmaceuticals has benefitted from Tavalisse's sustained outperformance, driving increasing net income and attractive valuation metrics. Gavreto's recent flat performance is offset by RIGL's overall drug portfolio momentum and cash position improvement. R289 could have potential in lower-risk myelodysplastic syndromes, and additional clinical data provides a 2026 catalyst.
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Rigel Pharma: Formulating A Game Plan For 2026
Rigel Pharmaceuticals delivered strong 2025 results, with Q3 revenue of $69.5M, net income of $27.9M, and cash of $137.1M. RIGL raised 2025 revenue guidance to $285M–$290M, projecting 55%–59% commercial growth, driven by TAVALISSE, REZLIDHIA, and GAVRETO. 2026 is expected to be a transition year, with flat revenue and declining EPS due to higher R&D spend, before a return to double-digit growth in 2027.
Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel Pharma: Q3 Earnings Showcase Robust Growth
Rigel Pharma is a profitable biotech with three FDA-approved drugs, experiencing accelerating revenue growth led by Tavalisse's strong performance. RIGL trades at a significant discount to biotech peers, despite a 186% YTD stock rise and robust 2025 sales guidance, making it a contrarian BUY. Continued momentum in Tavalisse and emerging growth from Rezlidhia position RIGL for potential outperformance, with additional upside from clinical pipeline catalysts.
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong Buy
Rigel (RIGL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Rigel Pharmaceuticals, Inc. ( RIGL ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Raymond Furey - Executive VP, Chief Compliance Officer, General Counsel & Corporate Secretary Raul Rodriguez - President, CEO & Director David Santos - Executive VP & Chief Commercial Officer Lisa Rojkjaer - Executive VP & Chief Medical Officer Dean Schorno - Executive VP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Mohamad Amin Makarem - Jefferies LLC, Research Division Presentation Operator Greetings, and welcome to the Rigel Pharmaceuticals Financial Conference Call for the Third Quarter 2025.
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.7 per share a year ago.
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect
RIGL's rising Tavalisse sales, along with incremental sales from Rezlidhia and Gavreto, could power another earnings beat in the quarter to be reported.
